#Birelentinib

Dizal to Bring Golidocitinib, Birelentinib and GW5282 Data to ASH 2026

Dizal will present three oral and five poster presentations at the ASH 2026 Annual Meeting, covering golidocitinib in T-cell lymphoma and HLH, birelentinib in CLL/SLL, and first-time clinical data for GW5282 in relapsed or refractory non-Hodgkin lymphoma.